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CONSORT	2010	checklist	of	information	to	include	when	reporting	a	randomised	trial*	
	
Myopia Outcome Study of Atropine in Children (MOSAIC): Design and Methodology	
	
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 3-4 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 5-7 
2b Specific objectives or hypotheses 7 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 8, Figure 2 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants 17,19 
4b Settings and locations where the data were collected 8 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
11,12 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9,10 
6b Any changes to trial outcomes after the trial commenced, with reasons  
Sample size 7a How sample size was determined 16 
7b When applicable, explanation of any interim analyses and stopping guidelines 13 
Randomisation:   11-12 
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking and block size) 11-12 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
11-12 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 11-12 
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interventions 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
12-13 
11b If relevant, description of the similarity of interventions 12 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 27-29 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 27-29 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
10 Figure 2 
13b For each group, losses and exclusions after randomisation, together with reasons  
Recruitment 14a Dates defining the periods of recruitment and follow-up 19-20 
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group  
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings  
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  
Other information  
Registration 23 Registration number and name of trial registry 8 
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 7 Figure 1 
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*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
